120 related articles for article (PubMed ID: 11406752)
1. Comparison of antimycobacterial activity of grepafloxacin against Mycobacterium avium with that of levofloxacin: accumulation of grepafloxacin in human macrophages.
Hirota M; Totsu T; Adachi F; Kamikawa K; Watanabe J; Kanegasaki S; Nakata K
J Infect Chemother; 2001 Mar; 7(1):16-21. PubMed ID: 11406752
[TBL] [Abstract][Full Text] [Related]
2. Comparative antimycobacterial activities of ofloxacin, ciprofloxacin and grepafloxacin.
Vacher S; Pellegrin JL; Leblanc F; Fourche J; Maugein J
J Antimicrob Chemother; 1999 Nov; 44(5):647-52. PubMed ID: 10552981
[TBL] [Abstract][Full Text] [Related]
3. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Kajitani H; Akaki T; Shishido S
Antimicrob Agents Chemother; 2000 Feb; 44(2):283-6. PubMed ID: 10639351
[TBL] [Abstract][Full Text] [Related]
4. Transport characteristics of grepafloxacin and levofloxacin in the human intestinal cell line Caco-2.
Yamaguchi H; Yano I; Saito H; Inui K
Eur J Pharmacol; 2001 Nov; 431(3):297-303. PubMed ID: 11730721
[TBL] [Abstract][Full Text] [Related]
5. MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis.
Heifets LB; Lindholm-Levy PJ
Antimicrob Agents Chemother; 1990 May; 34(5):770-4. PubMed ID: 2113793
[TBL] [Abstract][Full Text] [Related]
6. Distribution characteristics of levofloxacin and grepafloxacin in rat kidney.
Ito T; Yano I; Masuda S; Hashimoto Y; Inui K
Pharm Res; 1999 Apr; 16(4):534-9. PubMed ID: 10227708
[TBL] [Abstract][Full Text] [Related]
7. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
Yamaguchi H; Yano I; Hashimoto Y; Inui KI
J Pharmacol Exp Ther; 2000 Oct; 295(1):360-6. PubMed ID: 10992002
[TBL] [Abstract][Full Text] [Related]
8. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
9. Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.
Bermudez LE; Inderlied CB; Kolonoski P; Wu M; Barbara-Burnham L; Young LS
Antimicrob Agents Chemother; 1996 Mar; 40(3):546-51. PubMed ID: 8851568
[TBL] [Abstract][Full Text] [Related]
10. Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group.
Bale MJ; Jones RN; Erwin ME
Diagn Microbiol Infect Dis; 1994 May; 19(1):65-8. PubMed ID: 7956017
[TBL] [Abstract][Full Text] [Related]
11. Determining the frequency of resistance of Streptococcus pneumoniae to ciprofloxacin, levofloxacin, trovafloxacin, grepafloxacin, and gemifloxacin.
Evans ME
Eur J Clin Microbiol Infect Dis; 2001 Dec; 20(12):883-5. PubMed ID: 11837640
[TBL] [Abstract][Full Text] [Related]
12. Ultrastructural characterization of murine limb buds after in vitro exposure to grepafloxacin and other fluoroquinolones.
Shakibaei M; Baumann-Wilschke I; Rücker M; Stahlmann R
Arch Toxicol; 2002 Jan; 75(11-12):725-33. PubMed ID: 11876506
[TBL] [Abstract][Full Text] [Related]
13. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).
Saito H; Sato K; Tomioka H; Dekio S
Tuber Lung Dis; 1995 Oct; 76(5):377-80. PubMed ID: 7495996
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
Odenholt I; Cars T; Lowdin E
J Antimicrob Chemother; 2000 Jul; 46(1):35-43. PubMed ID: 10882686
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of anaerobes to quinolones in the United States.
Hecht DW; Wexler HM
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
[TBL] [Abstract][Full Text] [Related]
16. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
Barry AL; Fuchs PC
J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
[TBL] [Abstract][Full Text] [Related]
17. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages.
Rastogi N; Labrousse V; Goh KS; De Sousa JP
Antimicrob Agents Chemother; 1991 Dec; 35(12):2473-80. PubMed ID: 1667250
[TBL] [Abstract][Full Text] [Related]
18. [In vitro antimycobacterial activity of a new quinolone, NM394].
Tomioka H; Sato K; Saito H
Kekkaku; 1993 Aug; 68(8):517-20. PubMed ID: 8397311
[TBL] [Abstract][Full Text] [Related]
19. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin.
Tomioka H; Saito H; Sato K
Antimicrob Agents Chemother; 1993 Jun; 37(6):1259-63. PubMed ID: 8392307
[TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
Bébéar CM; Renaudin H; Schaeverbeke T; Leblanc F; Bébéar C
J Antimicrob Chemother; 1999 May; 43(5):711-4. PubMed ID: 10382895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
